- lead - Panacea Biotec is a biotechnology company that has spent four decades moving from a small retail start-up to a global vaccine developer, and its story is best told through the complete journey of a child: it makes the vaccines that protect against life-threatening diseases, the nutrition products for early growth, and the complex medicines for ongoing health. The company was founded in 1984 and built its reputation by supplying more than 10 billion doses of oral polio vaccine to UNICEF and governments, playing a pivotal role in polio eradication. The recurring approach that explains everything else is a first-mover instinct in paediatric combination vaccines - it created the world's first fully liquid versions of the wP-based pentavalent, wP-based hexavalent, and wP-IPV pentavalent vaccines, each designed to reduce the number of injections a child needs.
Business segments
Three engines built around the same child-health arc - a vaccines platform that supplies the world's largest health agencies, a pharmaceutical formulations export business focused on complex generics, and a young consumer nutrition and baby-care brand now reaching over 10,000 Indian retailers.
1. Vaccines: where the world's largest health agencies come to buy
The company makes combination paediatric vaccines that pack protection against up to six diseases into a single injection, and it sells them through institutional tenders to UNICEF, PAHO, and Gavi - a business built on WHO pre-qualification and a track record of more than 10 billion polio doses supplied.
- First to market with fully liquid combinations - it launched the world's first fully liquid wP-based pentavalent vaccine (EasyFive-TT) in 2005, the first hexavalent (EasySix) in 2017, and the first wP-IPV pentavalent (EasyFourPol) in 2023-24, each eliminating the need for reconstitution at the point of use. Being first matters because combination vaccines reduce carbon emissions by over 60%, supply chain costs by over 50%, and biological waste by over 50% compared to separate injections, which is exactly what large procurement agencies want.
- WHO pre-qualification unlocks the tender book - EasyFive-TT and the bivalent oral polio vaccine (bOPV) are both WHO pre-qualified, so the company can bid on the institutional tenders that drive volume in this business. In practice, that means long-term supply awards: a US$ 127.30 million award from UNICEF and PAHO for EasyFive-TT covering 2023-2027, and a letter of award from UNICEF for 115 million doses of bOPV worth roughly ₹127 crore for calendar year 2025 alone.
- A pipeline built for the next tender cycle - the hexavalent vaccine EasySix is the market leader in India's private market for wP-based combinations, and Gavi's 2023 decision to adopt hexavalent vaccines into its global programme creates a market for over 250 million doses annually by 2030 in Gavi-eligible countries. The company's marketed and near-market vaccines are expected to cover over 46% of Gavi's demand in doses until 2030.
- Backward integration into the drug substance - the Lalru manufacturing site makes its own recombinant hepatitis B surface antigen, tetanus toxoid, Hib conjugate, and whole-cell pertussis antigens, so the company is not dependent on third-party suppliers for the biological building blocks of its vaccines. A capacity expansion funded by a US$20 million loan from the U.S. International Development Finance Corporation is scaling up wP and DT production to 70 million doses per annum.
- A patent wall around the hexavalent franchise - EasySix is protected by Indian Patent IN 272351, which the company successfully defended against Sanofi in the Delhi High Court; the suit was disposed of by the court in the company's favour on September 13, 2024, and under the settlement terms Sanofi agreed not to launch its competing hexavalent vaccine in India.
2. Pharmaceutical formulations: complex generics for export markets
After selling its domestic branded formulations business in 2022, the company now focuses entirely on making difficult-to-copy generic drugs - oncology injectables, transplant medicines, and nanotechnology-based products - for the US, Europe, and about 40 other countries.
- Nanotechnology as a differentiator - PacliAll (paclitaxel protein-bound particles) was launched in 2011 as the world's first generic version of Abraxane, a cancer drug that uses albumin nanoparticles to deliver the active ingredient. It was launched in Canada through Apotex as the first generic Abraxane in that market, and an ANDA for the US market has been accepted for filing by the USFDA.
- Manufacturing approved by tough regulators - the Baddi facility holds approvals from the USFDA, the EU's OGYÉI (Hungary), ANVISA Brazil, SAHPRA South Africa, and others, and it includes a dedicated oncology unit that can handle lyophilized injectables and liposomal products. The oncology facility is currently under a USFDA warning letter, but supplies to the US market are continuing while corrective measures are implemented.
- Front-end partners carry the commercial load - instead of building its own sales force in every country, PBPL works with established generic companies like Apotex, Bionpharma, and Breckenridge Pharmaceutical, who take the products through their distribution networks. Four products - Tacrolimus, Rizatriptan, Prasugrel, and Azacitidine - have already been commercialized in the US through these partnerships.
3. Nutrition and baby care: a consumer brand in the making
The company has entered the paediatric nutrition and baby-care market in India with its own brands - ChilRun for nutrition, NikoMom for diapers and skin care, and Staart Prime for infant formula - sold through paediatricians, over 10,000 retail outlets, and e-commerce platforms.
- Launched from a standing start in 2023 - the ChilRun paediatric nutrition range (including a no-sucrose variant) was launched in June 2023 and is now available in more than 10,000 retailers across India. The company followed up with NikoMom baby diapers and wipes in January 2025, four baby skin-care products in September 2025, and the Staart Prime infant milk substitute range in the same month.
- Own manufacturing, not contract packing - the Health Supplement Manufacturing Facility at Baddi became operational in April 2023 with an installed capacity of about 6 tonnes per day, and it holds FSSAI accreditation and GMP Codex compliance, so the company controls production quality for its nutrition products in-house.
- Selling where young parents shop - products are available on Amazon, Flipkart, Tata 1mg, and the company's own direct-to-consumer portal, alongside a hybrid supply model that integrates its existing CFA (carrying-and-forwarding agent) network into D2C deliveries. The company also acquired trademarks, copyrights, patents, designs, domain names, product formulations and technical know-how, customer database and digital marketing assets, etc. inter-alia, in relation to the brand name, Power Gummies - gummy-based nutraceuticals for hair, skin, and sleep - adding a format that appeals to a different consumer need.
Research and development
A ~153-person R&D team working across two centres has generated over 466 granted patents globally, and it supplies the pipeline for all three businesses - vaccines, complex generics, and nutrition products.
- OneStream Research Centre in New Delhi - this is the vaccine development hub, equipped for genetic engineering, molecular biology, fermentation, and purification, and it has built a high-cell-density E. coli platform for making recombinant antigens and proteins. It is where the dengue vaccine DengiAll, the 11-valent pneumococcal vaccine NuCoVac11, and the Mpox and betacoronavirus candidates were developed.
- SAMPANN R&D Centre at Lalru - this centre focuses on difficult-to-develop pharmaceutical formulations (it created the nanotechnology behind PacliAll) and also develops the nutrition and baby-care products, from baby cereals and bars to gummies, oils, and cosmetics.
- A global intellectual property estate - as of March 2025, the group had filed over 488 patent applications in over 65 countries, with over 466 patents granted globally (42 still active), plus roughly 575 trademark applications and about 103 registered copyrights.
Group structure and partners
The listed parent holds the vaccines business and the IP; a wholly-owned subsidiary runs pharma formulations and the new consumer brands; and a network of global health agencies and research institutions funds and de-risks the pipeline.
- Panacea Biotec Ltd is the listed entity that directly operates the vaccines business and owns the intellectual property for the key vaccines.
- Panacea Biotec Pharma Limited (PBPL) is the wholly-owned material subsidiary that houses pharmaceutical formulations, nutrition, and baby care, exporting to about 40 countries. It has an indirect US subsidiary, Panacea Biotec Inc., incorporated in Delaware in 2024, for selling health and wellness products and prescription drugs in the American market.
- Global health partnerships fund the pipeline - the dengue vaccine DengiAll is being advanced through a consortium of 10 partners across 9 countries under the DENSTAR project, with an €11.09 million contribution from the European Union's EDCTP3 programme. The betacoronavirus vaccine candidate is co-funded by CEPI with US$12.5 million and co-developed with BRIC-THSTI. The dengue strains themselves were in-licensed from the National Institutes of Health in the US.
- Serum Institute of India is a key commercial partner, supplying a constituent for EasySix and collaborating on introducing the hexavalent vaccine in developing countries.